Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

by Thomas J. Semrad, David R. Gandara, Primo N. Lara
Published 2011-03-01

Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012

by JR, Primo N. LARA, Tianhong LI, Philip C. MACK, David R. GANDARA, Roy S. HERBST
Published 2010-03-01

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry

by Suzanne Miyamoto, Sandra L. Taylor, Dinesh K. Barupal, Ayumu Taguchi, Gert Wohlgemuth, William R. Wikoff, Ken Y. Yoneda, David R. Gandara, Samir M. Hanash, Kyoungmi Kim, Oliver Fiehn
Published 2015-04-01

American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions

by Gabriel N. Hortobagyi, Doug Pyle, Eduardo L. Cazap, Nagi S. El Saghir, Lawrence N. Shulman, Gary H. Lyman, Lowell E. Schnipper, Clement Adebayo Adebamowo, David R. Gandara, Julie Vose, Sandra L. Wong, Peter Yu
Published 2017-08-01

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

by Chong-Xian Pan, Hongyong Zhang, Clifford G Tepper, Tzu-yin Lin, Ryan R Davis, James Keck, Paramita M Ghosh, Parkash Gill, Susan Airhart, Carol Bult, David R Gandara, Edison Liu, Ralph W de Vere White
Published 2015-01-01

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider...

by Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela C. Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara
Published 2019-03-01